(Reuters) -Eli Lilly has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much muscle, due to strategic business reasons, according to a U.S. registry of clinical trials.
The drugmaker was testing the drug, bimagrumab, alone or in combination with Lilly’s tirzepatide, the active ingredient in its blockbuster obesity treatment, Zepbound.
Lilly was aiming to see how well and safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes.
The drugmaker did not immediately respond to a Reuters request for comment.
Bloomberg News reported the development earlier in the day.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shilpi Majumdar and Anil D’Silva)
Brought to you by www.srnnews.com
